摘要
目的探讨血浆脂蛋白相关磷脂酶A2(LP-PLA2)联合血清抵抗素对动脉粥样硬化性脑梗死患者预后转归的评估效果。方法回顾性分析2014年1月至2015年1月陕西省人民医院神经内科收治的144例动脉粥样硬化性脑梗死患者的病例资料,依据随访结果将其分为A组(预后不良,n=52)与B组(预后良好,n=92)。比较两组患者的血浆LP-PLA2水平和血清抵抗素水平,运用Cox比例风险模型分析法总结脑梗死患者的预后影响因素。结果A组患者的LP-PLA2水平为(269.35±88.01)mg/L、血清抵抗素水平为(24.37±4.82)mg/L,明显高于B组的(128.76±76.19)mg/L、(19.84±6.20)mg/L,差异具有统计学意义(P<0.05);通过Cox比例风险模型分析得出血清抵抗素(OR=1.779,P<0.05)与血浆LP-PLA2(OR=2.116,P<0.05)是预后的影响因素。结论血浆LP-PLA2联合血清抵抗素对动脉粥样硬化性脑梗死患者预后有较好的预测效果,有借鉴与推广价值。
Objective To explore the effect of plasma lipoprotein related phospholipase A2(LP-PLA2)combined with serum resistin on the prognosis of patients with atherosclerotic cerebral infarction.Methods A retrospective analysis on 144 patients with atherosclerotic cerebral infarction admitted to the Department of Neurology,Shaanxi Provincial People's Hospital during January 2014 to January 2015,according to the follow-up results,they were divided into group A(poor prognosis,n=52)and group B(good prognosis,n=92).Serum levels of LP-PLA2 and resistin were compared between these two groups.Cox proportional hazard model analysis was used to summarize the prognostic factors of patients with cerebral infarction.Results Serum levels of LP-PLA2 and resistin in patients of group A were(269.35±88.01)mg/L and(24.37±4.82)mg/L respectively,they were significantly higher than those in group B[(128.76±76.19)mg/L and(19.84±6.20)mg/L],with statistically significant difference(P<0.05).The Cox proportional risk model analysis showed that serum resistin(OR=1.779,P<0.05)and LP-PLA2(OR=2.116,P<0.05)were important factors influencing the prognosis.Conclusion Plasma LP-PLA2 combined with serum resistin have good predictive effect on the prognosis of patients with atherosclerotic cerebral infarction,and they have referential and promotion value.
作者
杨骏
罗维
刘倩
王琰
YANG Jun;LUO Wei;LIU Qian(Department of Neurology,Shaanxi Provincial Ppeople's Hospital,Xi'an Shaanxi 710068,China;Clinical Laboratory,Hospital of Traditional Chinese Medicine,Ankang Shaanxi 725000,China;Liu Qian Clinic,Weicheng District,Xianyang Shaanxi 712000,China)
出处
《临床和实验医学杂志》
2019年第21期2313-2316,共4页
Journal of Clinical and Experimental Medicine
基金
陕西省卫生厅科研基金项目(编号:2015JM4029)